B-NDG hB2M/HLA-A2.1 mice plus|BioMice

Please enter keyword

Gene Editing

By species

By technologies

By strategies

Animal & Cell Models

Humanized animal models

Immune checkpoint humanized mice

Cytokine humanized mice

GPCR humanized mice

Other humanized mice

KO mouse models

Drug target knockout mice

Tool mice

Immunodeficient mice/rats

B-NDG series immunodeficient mice

Other immunodeficient mice/rats

Cell lines

Humanized cell lines

Mouse derived cell lines

Reporter cell lines

Other cell lines

Aged mice

Disease mouse models

Oncology Disease

Autoimmune Disease

Nervous System Disease

Metabolic Disease

Orthopedic Disease

Ophthalmic Disease

Cardiovascular diseases

Urinary System Disease

Surgical disease

Rare Disease

Pharmacology Services

Therapeutic area

Oncology

Metabolic diseases

Autoimmune diseases

Inflammatory diseases

Types of services

In vivo pharmacology

Ex vivo pharmacology

In vitro pharmacology

Pharmacokinetics (PK) assays

Pathological/Toxicological assays

Model/method development

Molecule type

Technology

Resources & Activities

Technical support

News & events

Other Services

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

About Us

Biocytogen animal center

Certifications

Join us

Biocytogen

English|Chinese

English

Chinese

Order

*Country :

China

U.S.A

France

Germany

Netherlands

United Kingdom

Japan

South Korea

Israel

Austria

Hong Kong, China

New Zealand

Russia

Singapore

Taiwan, China

India

Åland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua & Barbuda

Argentina

Armenia

Aruba

Ascension Island

Australia

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

British Indian Ocean Territory

British Virgin Islands

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Canary Islands

Cape Verde

Caribbean Netherlands

Cayman Islands

Central African Republic

Ceuta & Melilla

Chad

Chile

China

Christmas Island

Cocos (Keeling) Islands

Colombia

Comoros

Congo - Brazzaville

Congo - Kinshasa

Cook Islands

Costa Rica

Côte d’Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czechia

Denmark

Diego Garcia

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

Indonesia

Iran

Iraq

Ireland

Isle of Man

Italy

Jamaica

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macau, China

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

New Caledonia

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

North Korea

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territories

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn Islands

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Rwanda

Samoa

San Marino

São Tomé & Príncipe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Sint Maarten

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia & South Sandwich Islands

South Sudan

Spain

Sri Lanka

St. Barthélemy

St. Helena

St. Kitts & Nevis

St. Lucia

St. Martin

St. Pierre & Miquelon

St. Vincent & Grenadines

Sudan

Suriname

Svalbard & Jan Mayen

Swaziland

Sweden

Switzerland

Syria

Tajikistan

Zimbabwe

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad & Tobago

Tristan da Cunha

Tunisia

Turkey

Turkmenistan

Turks & Caicos Islands

Tuvalu

U.S. Outlying Islands

U.S. Virgin Islands

Uganda

Ukraine

United Arab Emirates

United Nations

United States

Uruguay

Uzbekistan

Vanuatu

Vatican City

Venezuela

Vietnam

Wallis & Futuna

Western Sahara

Yemen

Zambia

*States :

*City :

*Name :

*Telephone :

*Company :

*Job Title :

*Email :

*Verification Code :

Submit

Home

Animal&Cell Models

Immunodeficient mice/rats

B-NDG series immunodeficient mice

Text

B-NDG hB2M/HLA-A2.1 mice plus

Database

Click order

Strain Name	NOD.CB17-Prkdc^scidIl2rg^tm1BcgenB2m^{tm1(B2M/HLA-A2.1)Bcgen}Fcgrt^{tm1(B2m/Fcgrt)Bcgen}/Bcgen	Common Name	B-NDG hB2M/HLA-A2.1 mice plus
Background	B-NDG mice	Catalog number	112449
Aliases	B2m: Ly-m11, beta2-m, beta2m HLA-A: HLAA Fcgrt : Fc receptor, IgG, alpha chain transporter,as known as Fcrn

Model validation

Determination of plasma concentrations of human IgG in different mice

Pharmacokinetic characteristic of B-NDG hB2M/HLA-A2.1 mice plus has no difference compared with B-NDG mice. B-NDG mice, B-NDG HLA-A2.1 mice, B-NDG hB2M/HLA-A2.1 mice plus were treated with YH001 (anti-human CTLA4 antibody) (n=4). Blood samples were collected at different time point for the PK assay. The results showed that the PK results of B-NDG hB2M/HLA-A2.1 mice plus group was similar to that in B-NDG mice, and the drug concentration of B-NDG HLA-A2.1 mice group could not be measured at the time point 4 days later. Results indicated that when compared with B-NDG HLA-A2.1 mice, the B-NDG hB2M/HLA-A2.1 mice plus can significantly extend the half-life of antibody drugs in mice.

Technical support

News&events

Quality Assurance

Genetic background detection